Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer’s disease
Open Access
- 9 May 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Lipids in Health and Disease
- Vol. 12 (1), 68-14
- https://doi.org/10.1186/1476-511x-12-68
Abstract
Background Alzheimer’s disease (AD), the most common cause of dementia among neurodegenerative diseases, afflicts millions of elderly people worldwide. In addition to amyloid-beta (Aβ) peptide and phosphorylated tau, lipid dysregulation is suggested to participate in AD pathogenesis. However, alterations in individual lipid species and their role in AD disease progression remain unclear. Methods We performed a lipidomic analysis using brain tissues and plasma obtained from mice expressing mutated human amyloid precursor protein (APP) and tau protein (Tg2576×JNPL3) (APP/tau mice) at 4 (pre-symptomatic phase), 10 (early symptomatic) and 15 months (late symptomatic). Results Levels of docosahexaenoyl (22:6) cholesterol ester (ChE) were markedly increased in APP/tau mice compared to controls at all stages examined. Several species of ethanolamine plasmalogens (pPEs) and sphingomyelins (SMs) showed different levels between brains from APP/tau and control mice at various stages of AD. Increased levels of 12-hydroxyeicosatetraenoic acid (12-HETE) during the early symptomatic phase were consistent with previous reports using human AD brain tissue. In addition, 19,20-dihydroxy-docosapentaenoic acid (19,20-diHDoPE) and 17,18-dihydroxy-eicosatetraenoic acid (17,18-diHETE), which are produced from docosahexaenoic acid and eicosapentaenoic acid via 19,20-epoxy-docosapentaenoic acid (19,20-EpDPE) and 17,18-epoxy-eicosatetraenoic acid (17,18-EpETE), respectively, were significantly increased in APP/tau brains during the pre-symptomatic phase, and concomitant increases occurred in plasma. Several arachidonic acid metabolites such as prostaglandin D2 (PGD2) and 15-hydroxyeicosatetraenoic acid (15-HETE), which have potential deteriorating and protective actions, respectively, were decreased in the early symptomatic phase of APP/tau mice. Significant decreases in phosphatidylcholines and PEs with polyunsaturated fatty acids were also detected in the late symptomatic phase, indicating a perturbation of membrane properties. Conclusion Our results provide fundamental information on lipid dysregulation during various stages of human AD.Keywords
This publication has 36 references indexed in Scilit:
- Hypercholesterolemia accelerates intraneuronal accumulation of Aβ oligomers resulting in memory impairment in Alzheimer's disease model miceLife Sciences, 2012
- Effects of Membrane Lipids on the Activity and Processivity of Purified γ-SecretaseBiochemistry, 2012
- Plasma and Brain Fatty Acid Profiles in Mild Cognitive Impairment and Alzheimer's DiseaseJournal of Alzheimer's Disease, 2012
- Comparative Lipidomic Analysis of Mouse and Human Brain with Alzheimer DiseaseJournal of Biological Chemistry, 2012
- Omega-3 polyunsaturated fatty acids in Alzheimer's disease: key questions and partial answers.Current Alzheimer Research, 2011
- Direct and Potent Regulation of γ-Secretase by Its Lipid MicroenvironmentOnline Journal of Public Health Informatics, 2008
- A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer diseaseJCI Insight, 2005
- Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic PerspectiveCell, 2005
- Alzheimer's DiseaseThe New England Journal of Medicine, 2004
- Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APPScience, 2001